Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
Surface Oncology (Nasdaq: SURF) announced that CEO Rob Ross will participate in a fireside chat at the 2023 Guggenheim Oncology Days conference in New York City on February 9, 2023, at 1:35 p.m. ET. The session will be available via a live audio webcast, accessible on the company's Investors & Media section. Surface is focused on developing next-generation immunotherapies that target the tumor microenvironment, with programs including SRF388 and SRF114, targeting IL-27 and CCR8 respectively. Collaborations with Novartis and GlaxoSmithKline further bolster their pipeline. For more details, visit the Surface Oncology website.
- None.
- None.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Days conference in New York City on Thursday, February 9, 2023, at 1:35 p.m. ET.
A live audio webcast of the session may be accessed by visiting the Events page on the Investors & Media section of the Surface Oncology website. In addition, a replay of the webcast will be available on the company’s website following the presentation.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs; SRF388, a Phase 2 program which targets IL-27, and SRF114, a Phase 1 program which selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. In addition, Surface has two partnerships with major pharmaceutical companies; a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com
FAQ
What is the date of the Guggenheim Oncology Days conference for Surface Oncology?
Who is speaking at the Guggenheim Oncology Days conference for Surface Oncology?
What time will Surface Oncology's presentation take place at the conference?
How can I access the live webcast of Surface Oncology's conference presentation?
What are the key programs Surface Oncology is developing?
